Table 3.
Comparison between baseline and follow-up values of HbA1c, serum creatinine and eGFR before and after initiating combination antidiabetic therapy
| Treatment Groups | N | HbA1c (%) | Serum creatinine (mg/dl) | eGFR (ml/min/1.73m2) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sitagliptin add-on Metformin | Median (IQR) | Z Statistic | p-value* | Median (IQR) | Z Statistic | p-value* | Median (IQR) | Z Statistic | p-value* | |
| Baseline | 79 | 9.4 (2.8) | -7.723 | < 0.001 | 0.9 (0.1) | -1.905 | 0.057 | 80.3 (20.07) | -1.903 | 0.057 |
| After 3 months | 79 | 7 (2.2) | 0.9 (0.1) | 82.07 (20.9) | ||||||
| Empagliflozin add-on Metformin | ||||||||||
| Baseline | 76 | 9.4 (2.2) | -7.576 | < 0.001 | 1.0 (0.4) | -2.551 | 0.01 | 73.3 (32.08) | -2.734 | 0.006 |
| After 3 months | 76 | 7.2 (2.1) | 1.0 (0.2) | 78.3 (28.7) | ||||||
*p-value was calculated using the Wilcoxon Signed-Ranks test